FDA Approved: KISQALI — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Kisqali (ribociclib) submitted by Novartis Pharmaceuticals Corporation, updating the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI (RIBOCICLIB)